An Open-label, Single-dose Study to Evaluate the Pharmacokinetics, Biotransformation and Excretion of [14C]AMG 416 in Patients With End Stage Renal Disease Receiving Dialysis
Phase of Trial: Phase I
Latest Information Update: 19 Apr 2017
Price : $35 *
At a glance
- Drugs Etelcalcetide (Primary)
- Indications Secondary hyperparathyroidism
- Focus Pharmacokinetics
- Sponsors Amgen
- 30 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Jun 2014 Planned End Date changed from 1 Jun 2014 to 1 Sep 2014 as reported by ClinicalTrials.gov.
- 31 Mar 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.